Pharmaceutical company LTR Pharma (ASX:LTP) and drug delivery firm Aptar Pharma entered into a co-development agreement for SPONTAN nasal spray for global markets, according to a Tuesday filing with the Australian bourse.
The main goal of the agreement is to commercialize SPONTAN in the US and other major markets. The nasal spray is designed to treat erectile dysfunction faster than tablets, the filing said.
Shares of LTR Pharma jumped over 18% in recent trade.
Price (AUD): $1.14, Change: $+0.18, Percent Change: +18.13%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments